A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Public ClinicalTrials.gov record NCT05032040. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.
Study identification
- NCT ID
- NCT05032040
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 170 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 21, 2022 (Actual)
- Primary completion
- Oct 15, 2025 (Estimated)
- Completion
- Dec 30, 2025 (Estimated)
- Last update posted
- Feb 7, 2025
2022 – 2025
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates, PC - NAHOA | Prescott | Arizona | 86301 | — |
| UCSD Moores Cancer Center | La Jolla | California | 92037 | — |
| Valkyrie Clinical Trials | Los Angeles | California | 90067 | — |
| UCLA Medical Center | Los Angeles | California | 92004 | — |
| Kaiser Permanente Medical Group | Riverside | California | 92505 | — |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94158 | — |
| Rocky Mountain Cancer Centers | Aurora | Colorado | 80012 | — |
| Medical Oncology Hematology Consultants, PA | Newark | Delaware | 19713 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Winship Cancer Institute, Emory University | Atlanta | Georgia | 30322 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Comprehensive Cancer Centers of Nevada-Southern Hills | Las Vegas | Nevada | 89148 | — |
| NYU Langone Health | New York | New York | 10016 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| University of Pennsylvania Health System | Philadelphia | Pennsylvania | 19104 | — |
| Texas Oncology - Central South | Austin | Texas | 78745 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05032040, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 7, 2025 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05032040 live on ClinicalTrials.gov.